AU2002358569A1 - Screening method for compounds that modulate neuronal activity - Google Patents

Screening method for compounds that modulate neuronal activity

Info

Publication number
AU2002358569A1
AU2002358569A1 AU2002358569A AU2002358569A AU2002358569A1 AU 2002358569 A1 AU2002358569 A1 AU 2002358569A1 AU 2002358569 A AU2002358569 A AU 2002358569A AU 2002358569 A AU2002358569 A AU 2002358569A AU 2002358569 A1 AU2002358569 A1 AU 2002358569A1
Authority
AU
Australia
Prior art keywords
compounds
screening method
neuronal activity
modulate neuronal
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002358569A
Other languages
English (en)
Inventor
Hugo Albrecht
Mirna Kvajo
Denis Monard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Original Assignee
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Publication of AU2002358569A1 publication Critical patent/AU2002358569A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
AU2002358569A 2001-11-30 2002-11-29 Screening method for compounds that modulate neuronal activity Abandoned AU2002358569A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0128793.7 2001-11-30
GBGB0128793.7A GB0128793D0 (en) 2001-11-30 2001-11-30 Screening method for compounds that modulate neuronal activity
PCT/EP2002/013519 WO2003046552A2 (en) 2001-11-30 2002-11-29 Screening method for compounds that modulate neuronal activity

Publications (1)

Publication Number Publication Date
AU2002358569A1 true AU2002358569A1 (en) 2003-06-10

Family

ID=9926820

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002358569A Abandoned AU2002358569A1 (en) 2001-11-30 2002-11-29 Screening method for compounds that modulate neuronal activity

Country Status (6)

Country Link
US (1) US20050019261A1 (enExample)
EP (1) EP1459063A2 (enExample)
JP (1) JP2005510250A (enExample)
AU (1) AU2002358569A1 (enExample)
GB (1) GB0128793D0 (enExample)
WO (1) WO2003046552A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658912B2 (en) * 2003-06-20 2010-02-09 University Of Massachusetts Spatial evolution of neural activity
US9018440B2 (en) * 2006-10-27 2015-04-28 Stowers Institute For Medical Research Fluorescent mouse model

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079880A1 (en) * 1990-04-24 1991-10-25 William E. Van Nostrand Purification, detection and methods of use of protease nexin-2
US5470970A (en) * 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
US5777194A (en) * 1995-04-26 1998-07-07 Cephalon, Inc. Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
US6008020A (en) * 1996-10-11 1999-12-28 Human Genome Sciences Brain-associated inhibitor of tissue-type plasminogen activator
WO2000023593A2 (en) * 1998-10-16 2000-04-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Molecular pathogenicide mediated plant disease resistance

Also Published As

Publication number Publication date
JP2005510250A (ja) 2005-04-21
WO2003046552A2 (en) 2003-06-05
WO2003046552A3 (en) 2003-12-04
EP1459063A2 (en) 2004-09-22
GB0128793D0 (en) 2002-01-23
US20050019261A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
AU2002256619A1 (en) Method for identifying herbicidally active substances
AU2002249116A1 (en) Gene library for screening methods
AU2003299083A1 (en) A method for treating severe tinnitus
AU2003214055A1 (en) Method for screening for compounds having hdac inhibitory activity
AU5787999A (en) Method for treating neurodegenerative disorders
AU2002249467A1 (en) Screening method
AU2003277663A1 (en) Screening method
AU2001294895A1 (en) Methods for identifying compounds that modulate biofilm activity
AU2002237261A1 (en) Rapid method for screening compounds for in vivo activity
AU2002247215A1 (en) Method for screening compounds
AU1553101A (en) Screening method
AU2002358569A1 (en) Screening method for compounds that modulate neuronal activity
AU5272800A (en) Method for applying bsr elastomer
AU2002258787A1 (en) Screening methods for identifying ligands
AU5485499A (en) Method of screening for compounds that modulate the activity of a molecular target
GB9908676D0 (en) Method for screening compounds
AU2002317009A1 (en) Screening method for identifying cancer therapy-relevant compounds
AU4856501A (en) Screening method for compounds
AU2002317093A1 (en) Screening processes for agents modulating cholesterol levels
AU2003206594A1 (en) Screening for modulators of pkng activity
AU2002354247A1 (en) Screening method
AU2003212783A1 (en) Method for screening therapeutic agents for modulation of ejaculatory response
AU2003228813A1 (en) Methods for treating neuronal disorders
AU2002235892A1 (en) Screening method for identifying medicaments
AU2003217008A1 (en) Screening method

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase